Results
FN075 did not precipitate motor
impairment in the AAV-α-synuclein model
One critical aspect of Parkinson’s disease is the progressive emergence
of motor impairments. In unilateral models of the disease, this
manifests as deficits on contralateral side of the body to the site
injected, while the ipsilateral side of the body remains unaffected.
Hence, the animals were subjected to a series of lateralised motor tests
to investigate whether the single or combined Parkinsonian insults could
provoke motor impairment specifically on the contralateral side.
However, relative to the Control group, neither AAV-α-synuclein nor
FN075, either alone or in sequence, induced any significant
contralateral motor deficit in any of the tests (Fig. 1; Stepping: Group
x Time, F(15, 180) = 0.66, p> 0.05; Whisker: Group x Time, F(15,
180) = 0.84, p > 0.05); Corridor Group x Time,F(15, 180) = 0.73, p > 0.05).
Fig. 1. Effect of AAV-α-synuclein and/or FN075 on contralateral
motor function. Neither unilateral administration of AAV-α-synuclein
nor FN075, alone or sequentially, was sufficient to induce contralateral
motor deficits in the Stepping, Whisker or Corridor tests. Data are
represented as mean ± SEM with n = 10 animals per group, and were
analysed by two-way ANOVA with repeated measures. Infusion days are
represented by dashed lines.